CLN-049
Phase 1Small molecule
CLN-049 is one of 55 small molecule programs targeting AML - Acute Myeloid Leukemia. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Myelodysplastic Syndrome
#DrugCompanyPhaseTrials
1Dacogen
Sun Pharmaceutical Industries, Inc.Approved
Neoral
NovartisApproved
Exjade
NovartisApproved
Cytosar
TevaPhase 3
Venclexta
AbbViePhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Fludara
SanofiPhase 3
Afinitor
NovartisApproved
Danocrine
SanofiApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CLN-049. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCullinan Therapeutics Inc.